{"denoms":[{"counts":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"68"},{"groupId":"BG002","value":"14"},{"groupId":"BG003","value":"92"}],"units":"Participants"}],"groups":[{"description":"Participants with relapsed/refractory MCL received CTE consisting of fludarabine 30 mg/m\\^2/day and cyclophosphamide 500 mg/m\\^2/day IV infusion for 3 days followed by a single infusion of axicabtagene ciloleucel at a targeted dose of 2 x 10\\^6 anti-CD19 CAR T cells/kg on Day 0.","id":"BG000","title":"2 x 10^6 Axicabtagene Ciloleucel"},{"description":"Participants with relapsed/refractory MCL received conditioning chemotherapy consisting of fludarabine 30 mg/m\\^2/day and cyclophosphamide 500 mg/m\\^2/day IV infusion for 3 days followed by a single infusion of brexucabtagene autoleucel at a targeted dose of 2 x 10\\^6 anti-CD19 CAR T cells/kg, with a maximum dose of 2 x 10\\^8 anti-CD19 CAR T cells for participants ≥ 100 kg on Day 0.","id":"BG001","title":"Cohort 1: 2 x 10^6 Brexucabtagene Autoleucel"},{"description":"Participants with relapsed/refractory MCL received conditioning chemotherapy consisting of fludarabine 30 mg/m\\^2/day and cyclophosphamide 500 mg/m\\^2/day IV infusion for 3 days followed by a single infusion of brexucabtagene autoleucel at a targeted dose of 0.5 x 10\\^6 anti-CD19 CAR T cells/kg, with a maximum dose of 0.5 x 10\\^8 anti-CD19 CAR T cells for participants ≥ 100 kg on Day 0.","id":"BG002","title":"Cohort 2: 0.5 x 10^6 Brexucabtagene Autoleucel"},{"description":"Total of all reporting groups","id":"BG003","title":"Total"}],"measures":[{"calculatePct":false,"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"29"},{"groupId":"BG002","value":"11"},{"groupId":"BG003","value":"44"}]}],"title":"< 65 years"},{"categories":[{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"39"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"48"}]}],"title":">= 65 years"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Age, Customized","unitOfMeasure":"Participants"},{"calculatePct":false,"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"11"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"15"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"57"},{"groupId":"BG002","value":"11"},{"groupId":"BG003","value":"77"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"calculatePct":false,"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"11"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"13"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"55"},{"groupId":"BG002","value":"12"},{"groupId":"BG003","value":"76"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"3"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"calculatePct":false,"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"62"},{"groupId":"BG002","value":"13"},{"groupId":"BG003","value":"85"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"}],"title":"Native Hawaiian or other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"5"}],"title":"Others"}],"title":"Race"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"2"}]}],"title":"Netherlands"},{"categories":[{"measurements":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"62"},{"groupId":"BG002","value":"14"},{"groupId":"BG003","value":"86"}]}],"title":"United States"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"3"}]}],"title":"France"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"}]}],"title":"Germany"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"}],"populationDescription":"The Safety Analysis Set included all participants treated with any dose of anti-CD19 CAR T cells."}